

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/540,348	First Named Inventor: Richard W A Luke
371 Filing Date: June 21, 2005	Attorney Docket No.: 100877-1P US
Examiner: Rao, Deepak R	Group Art Unit : 1624
Customer No.: 44992	Confirmation No.: 2539
Title: THERAPEUTIC AGENTS	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Response to Restriction Requirement

Sir:

In response to the Non-Final Office Action dated 17 March 2008, applicants hereby elect, with traverse, Group I, claims 1-2 and 6-12, drawn to compounds of formula (I) wherein Y is N, corresponding composition and method of use. Claims 1-2 and 6-12 encompass the elected invention.

Remarks/Arguments

Applicants respectfully traverse the requirement under 35 USC 372 on the ground that the presently claimed invention meets the unity of invention requirement.

We submit that there is a special technical feature that unites the presently claimed compounds and that distinguishes them all from the prior art.

The presently claimed compounds form a group of compounds that share a common core structure, which has the following essential features:

- i) An aromatic azine (i.e. a pyrimidine or pyridine ring);
- ii) An azole (i.e. a 5-membered ring containing nitrogen and an additional heteroatom G, which ring is limited to an imidazole, oxazole or thiazole);
- iii) An unsaturated linker group L as defined;